MovDisordV3, Main, Exploration, bibRecord, 001D25

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

Identifieur interne : 001D25 ( Main/Exploration ); précédent : 001D24; suivant : 001D26

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

Auteurs : Bonnie P. Hersh [États-Unis] ; Nancy L. Earl [États-Unis] ; Robert A. Hauser [États-Unis] ; Mark Stacy [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2010-05-15.

RBID : ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2

Descripteurs français

Pascal (Inist)
- Echelle d'évaluation, Fluctuation, Homme, Libération, Maladie de Parkinson, Pathologie du système nerveux, Ropinirole, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Delayed-Action Preparations, Dopamine Agonists (therapeutic use), Double-Blind Method, Evaluation scale, Female, Fluctuations, Human, Humans, Indoles (therapeutic use), Male, Movement Disorders (diagnosis), Movement Disorders (epidemiology), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Release, Ropinirole, Severity of Illness Index, Treatment, Treatment Outcome, Unified Parkinson's Disease Rating Scale, efficacy, motor fluctuations, ropinirole prolonged release.
MESH :
- chemical , therapeutic use : Dopamine Agonists, Indoles.
- chemical : Delayed-Action Preparations.
- diagnosis : Movement Disorders.
- drug therapy : Parkinson Disease.
- epidemiology : Movement Disorders, Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Severity of Illness Index, Treatment Outcome.

Abstract

We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society

Url:

https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/pdf

DOI: 10.1002/mds.23040

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23040</idno>
<idno type="url">https://api.istex.fr/document/60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000B00</idno>
<idno type="wicri:Area/Istex/Curation">000B00</idno>
<idno type="wicri:Area/Istex/Checkpoint">000A04</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20461810</idno>
<idno type="wicri:Area/PubMed/Corpus">001828</idno>
<idno type="wicri:Area/PubMed/Curation">001828</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001917</idno>
<idno type="wicri:Area/Ncbi/Merge">002B74</idno>
<idno type="wicri:Area/Ncbi/Curation">002B74</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002B74</idno>
<idno type="wicri:Area/Main/Merge">002161</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0288331</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B21</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002198</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A91</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Hersh B:early:treatment:benefits</idno>
<idno type="wicri:Area/Main/Merge">002678</idno>
<idno type="wicri:Area/Main/Curation">001D25</idno>
<idno type="wicri:Area/Main/Exploration">001D25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations</title>
<author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Harvard Vanguard Medical Associates, Boston Massachusetts</wicri:regionArea>
<wicri:noRegion>Boston Massachusetts</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Clinical Neurosciences, GlaxoSmithKline, Research Triangle Park, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Neurology, Department of Medicine, Duke University, Durham, North Carolina</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-05-15">2010-05-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="927">927</biblScope>
<biblScope unit="page" to="931">931</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2</idno>
<idno type="DOI">10.1002/mds.23040</idno>
<idno type="ArticleID">MDS23040</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Delayed-Action Preparations</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Evaluation scale</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Humans</term>
<term>Indoles (therapeutic use)</term>
<term>Male</term>
<term>Movement Disorders (diagnosis)</term>
<term>Movement Disorders (epidemiology)</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Release</term>
<term>Ropinirole</term>
<term>Severity of Illness Index</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>Unified Parkinson's Disease Rating Scale</term>
<term>efficacy</term>
<term>motor fluctuations</term>
<term>ropinirole prolonged release</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Severity of Illness Index</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Echelle d'évaluation</term>
<term>Fluctuation</term>
<term>Homme</term>
<term>Libération</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Ropinirole</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE‐PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2–24 mg/day) versus placebo in patients with moderate‐to‐advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in “off” time (adjusted mean treatment difference [AMTD] – 0.7 hours; 95% confidence interval [CI], –1.1, –0.2; P = 0.0029), and “on” time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, –3.1; 95%CI, –4.4, –1.8; P < 0.0001), activities of daily living score (AMTD, –1.1; 95%CI, –1.7, –0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once‐daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation. © 2010 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Caroline du Nord</li>
<li>Floride</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P." last="Hersh">Bonnie P. Hersh</name>
</noRegion>
<name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L." last="Earl">Nancy L. Earl</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:60626F07D831C78DFBBA7E5D3C622E3C4ECBBFB2
   |texte=   Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.